Janssen Cilag International

Company snapshot

Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Major, Chronic Lymphocytic Leukemia. NovaPharmaNews links 46 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (21), phase 2 (17), phase 1 (5).

• 46 active pipeline program(s) linked via ClinicalTrials.gov.
• 46 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Janssen Cilag International. Not investment advice.

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 50

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Janssen Cilag International.

1. Jun 8, 2026 Clinical update

   Ustekinumab Dose Based on BSA and Body Weight — Phase 3

2. Jun 8, 2026 Clinical update

   Topiramate — Approved

3. Jun 8, 2026 Clinical update

   Paliperidone palmitate — Phase 3

4. Jun 8, 2026 Clinical update

   OROS hydromorphone — Approved

5. Jun 8, 2026 Clinical update

   Guselkumab Dose 1 — Phase 3

View all clinical trial activity →

• What is Janssen Cilag International?

  Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Major, Chronic Lymphocytic Leukemia. NovaPharmaNews links 46 cli

• Is Janssen Cilag International publicly traded?

  Janssen Cilag International appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Janssen Cilag International develop or market?

  We link 37 drug profile(s) where Janssen Cilag International is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/janssen-cilag-international-nv-eu#company-drugs.

• What are the latest developments for Janssen Cilag International?

  In the last 12 months our linked public records show 46 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Janssen Cilag International focus on?

  Janssen Cilag International focuses on Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2 based on our analysis of their pipeline programs and drug development activities.